Physician profile
Claire E Brenner
NPI 1083787733
$4,587.90
in general payments reported to CMS, 2019-2025
15 companies · $58.44 in 2025
The $58.44 reported for 2025 was less than what a typical Infectious Disease provider received nationally (typical 2025 total: $187).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $530 · 2020: $20.49 · 2021: $534 · 2022: $729 · 2023: $1,518 · 2024: $1,199 · 2025: $58.44.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,732 · Education: $43.33.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,731.57 |
| Education | $43.33 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Viiv Healthcare Company | $1,380.23 | 2019-2024 | Dovato, Cabenuva, Apretude |
| Gilead Sciences, INC. | $889.23 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $750.04 | 2019-2024 | Delstrigo, Pifeltro, Dificid |
| Janssen Biotech, INC. | $467.69 | 2019-2023 | Symtuza |
| Paratek Pharmaceuticals, INC. | $287.05 | 2023-2024 | Nuzyra |
| Insmed, INC. | $244.07 | 2022-2024 | Arikayce |
| Janssen Products, LP | $168.99 | 2021-2022 | |
| Ferring Pharmaceuticals INC. | $137.69 | 2023-2024 | Rebyota |
| Pfizer INC. | $88.46 | 2023-2024 | |
| Abbvie INC. | $59.70 | 2021-2023 | Dalvance |
| Janssen Pharmaceuticals, INC | $39.22 | 2022-2023 | |
| Hospira, INC. | $27.57 | 2024 | |
| Allergan, INC. | $20.49 | 2020 | |
| Melinta Therapeutics, LLC | $14.47 | 2019 | |
| Nabriva Therapeutics, Plc | $13.00 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Claire Brenner listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.